Natrium Fusidat Essential Pharma (Fusidic Acid)

Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G (EF‑G) on the ribosome. This prevents the translocation step required for peptide chain elongation, halting bacterial growth and providing a bacteriostatic effect against susceptible Gram‑positive organisms.

The dosage and infusion rate of Natrium Fusidat Essential Pharma are determined by the prescribing clinician based on the infection severity, patient weight, renal and hepatic function, and local treatment guidelines. No fixed regimen is provided here.

Safety data for fusidic acid in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Fusidic acid is particularly effective against Staphylococcus aureus, including some methicillin‑resistant strains, and is often used when other agents such as clindamycin or vancomycin are unsuitable. Unlike beta‑lactams, it acts on protein synthesis, offering a different mechanism that can be useful in combination therapy.

Store at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from direct light, moisture, and extreme temperatures. Do not freeze. Follow standard aseptic techniques when preparing the intravenous solution.

The product is supplied for intravenous infusion. It should be reconstituted according to the manufacturer’s instructions and administered by a qualified healthcare professional using sterile technique, typically over a period dictated by the prescribed dose and patient tolerance.

Serious adverse events include anaphylactic reactions, significant liver enzyme elevations indicating hepatotoxicity, severe neutropenia, and rare skin disorders such as Stevens‑Johnson syndrome. Immediate medical attention is required if any of these symptoms develop.

Patients with known hypersensitivity to fusidic acid or any component of the formulation should avoid this product. Caution is also advised for individuals with severe hepatic or renal impairment, and it should be used only when clearly indicated in pregnant or breastfeeding women.